Login / Signup
Fenghao Shi
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 1
Top Topics
Skeletal Muscle
Tyrosine Kinase
Chemotherapy Induced
Epidermal Growth Factor Receptor
Top Venues
International journal of clinical pharmacy
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Yingdan Cao
,
Hongbin Yi
,
Fenghao Shi
,
XiaoXia Wei
,
Sheng Han
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.
International journal of clinical pharmacy
(2024)